Amendments to the Specification

Please amend the specification as follows:

a) Please replace the existing paragraph on page 7, lines 18-21 with the following paragraph:

Figure 11 shows the primers used (3NT5'OST [SEQ ID NO:[__]] <u>17</u>];
3NT3'OHT [SEQ ID NO:[__]] <u>18</u>]; 3NT5'KHT [SEQ ID NO:[__]] <u>19</u>];
3NT3'KST [SEQ ID NO:[[_]] <u>20</u>; 1NT5'[[OSI]] <u>ORI</u> [SEQ ID NO: [__]] <u>21</u>];
1NT3'Ori(s) [SEQ ID NO:[[6]] <u>22</u>]; 1NT5'KAN [SEQ ID NO:[[11]] <u>23</u>];
1NT3'KAN [SEQ ID NO:[[12]] <u>24</u>).

b) Please replace the existing paragraph on page 34, lines 1-6 with the following paragraph:

The vector/insert hybrid molecule depicted in Figure 10 was generated as follows. The ori-containing vector fragment was amplified from pET 19b (Novagen, Madison, WI) using primers (lower case letters indicate RNA residues; upper case letters indicate DNA residues) 5'OST (5'-CTGCTAAGTGAGCucGACAGATCGCTGAGATAGGTGC; SEQ ID NO:[[5]] 7) and 1N3'Ori(s)(5'-AAGCTTGCTAAGTAgGGCGTTTTTCCATAGGCTCCG; SEQ ID NO:[[6]] 8)

c) Please replace the existing paragraph on page 34, lines 7-11 with the following paragraph:

The vector fragment containing the Kanamycin resistance gene was amplified from pCR2.1 Topo (Invitrogen, Carlsbad, CA) using primers 1NT5'KAN (5' CTACCTAGCAAGCTuCTATCTGGACAAGGGAAAACG; SEQ ID NO:[[7]] 9) and T7 3'KAN (5'CCCTATAGTGAGTCGTATTAaGGCGAAAACTCTCAAGGATC; SEQ ID NO:[[8]] 10).

Page 2 of 11

Application Serial No. 09/910,354 Attorney Docket No.: 2003320-0032 d) Please replace the existing paragraph on page 34, lines 12-16 with the following paragraph:

The insert fragment containing the luciferase gene was amplified from pGI II basic (Promega, WI) using primers tCS1 (5' TTAATACGACTCACTATAGGGATGGAAGACGCCAAAAACATA; SEQ ID NO: [[9]] 11) and tCS8 (5'-GAGCTCACTTAGCAGTTACAATTTGGACTTTCCGCC; SEQ ID NO: [[10]] 12).

e) Please replace the existing paragraph on page 35, line 17 - page 37, line 5 with the following paragraph:

Those of ordinary skill in the art will appreciate that, as with Example 6, the ROC technique described in this Example utilizes primers containing internal ribonucleotide residues (in one case, 3 residues were used; in other cases only one) flanked by DNA residues. The overhangs created in these ROC PCR reactions, therefore, have only a single "ribo" residue; other overhang residues are DNA. In separate experiments, we have demonstrated that any individual ribonucleotide (i.e., rA, rG, rU, or rC) can act effectively to block extension of a complimentary strand by an appropriate DNA polymerase, so that overhangs are created (see, for example, Example 6). We have also showed that single 3'-Omethyl 2'-O-methyl residues are similarly effective. Primers containing 3'-Omethyl 2'-O-methyl residues can often be synthesized more easily (e.g., due to higher coupling efficiencies) than those containing inbanucleotides ribonucleotides, and will generally be more stable, so that they are preferred for many applications.

f) Please replace the existing paragraph on page 36, line 19 – page 37, line 9 with the following heading:

Application Serial No. 09/910,354 Attorney Docket No.: 2003320-0032 The following chimeric RNA/DNA primers were purchased from Oligo's Etc. (Willsonville, OR): (ribonucleotides are in lower case)

1NT 5'KAN-CTACCTAGCAAGCTuCTATCTGGACAAGGGAAAACG (SEQ ID NO:[[11]] 13)

1NT 3'KAN-GAGCTCACTTAGCAAGGCGAAAACTCTCAAGGA (SEQ ID NO:[[12]] 14)

1NT5'Ori- TTGCTAAGTGAGCUcGACAGATCGCTGAGATAGGTGC

TTGCTAAGTGAGCTcGACAGATCGCTGAGATAGGTGC (SEQ ID

NO:[[13]] 15) 1N3'Ori(s) 1NT3'Ori(s) -

AAGCTTGCTAAGTAgGGCGTTTTTCCATAGGCTCCG (SEQ ID NO:[[14]] 16). Primers 1NT 5'KAN and 1NT 3'KAN were used to amplify the Kan fragment from pCR 2.1 Topo (Invitrogen, Carlsbad, CA). Primers 1NT5'Ori and 1N3'Ori(s) 1NT3'Ori(s) were used to amplify the Ori fragment from pET 19b (Novagen, Madison, WI). The following cycles were performed: one cycle of 95°, 3', 48-60°, 2', 72°, 8'; followed by 35 cycles of 95°, 30sec, 48-60°, 30 sec, 72°, 3' for Ori fragment, 4.5' for Kan and Luc fragments. A final cycle with an 8'

72° step was performed in all cases.